Home » Stocks » PROF

Profound Medical Corp. (PROF)

Stock Price: $15.22 USD 0.01 (0.07%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 309.68M
Revenue (ttm) 5.21M
Net Income (ttm) -20.58M
Shares Out 20.35M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $15.22
Previous Close $15.21
Change ($) 0.01
Change (%) 0.07%
Day's Open 15.20
Day's Range 14.50 - 15.28
Day's Volume 57,253
52-Week Range 13.70 - 28.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TORONTO, July 22, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

2 days ago - GlobeNewsWire

TORONTO, July 15, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

1 week ago - GlobeNewsWire

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

1 month ago - GlobeNewsWire

TORONTO, May 19, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual Meeting of Shareholders ...

2 months ago - GlobeNewsWire

TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, i...

2 months ago - GlobeNewsWire

PROFOUND MEDICL (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

TORONTO, April 21, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

3 months ago - GlobeNewsWire

TORONTO, April 14, 2021 (GLOBE NEWSWIRE) --  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

3 months ago - GlobeNewsWire

TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free th...

4 months ago - GlobeNewsWire

PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -40.74% and -4.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

4 months ago - GlobeNewsWire

TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free the...

4 months ago - GlobeNewsWire

TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free the...

5 months ago - GlobeNewsWire

TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free the...

5 months ago - GlobeNewsWire

I have put an emphasis on value in 2021; however, I am not sitting still in my aggressive portfolio. I have added 2 new positions and added to a third. All 3 companies look to benefit from a return to n...

Other stocks mentioned: KLR, TLS
6 months ago - Seeking Alpha

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free the...

6 months ago - GlobeNewsWire

TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...

7 months ago - GlobeNewsWire

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FD...

7 months ago - GlobeNewsWire

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...

7 months ago - GlobeNewsWire

Profound Medical has unique differentiators via their TULSA-PRO procedure that provide a breakthrough in an otherwise complex treatment domain. The company has faced headwinds from COVID-19 this year, b...

8 months ago - Seeking Alpha

TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...

8 months ago - GlobeNewsWire

Profound Medical Corp. (PROF) CEO Arun Menawat on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...

8 months ago - GlobeNewsWire

TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine re...

9 months ago - GlobeNewsWire

TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combi...

10 months ago - GlobeNewsWire

Profound Medical: Momentum Continues To Build

11 months ago - Seeking Alpha

TORONTO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combin...

11 months ago - GlobeNewsWire

Profound Medical Corp. (PROF) CEO Arun Menawat on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -43.48% and -1.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combin...

11 months ago - GlobeNewsWire

TORONTO, July 22, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combin...

1 year ago - GlobeNewsWire

TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced underwritten ...

1 year ago - GlobeNewsWire

TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offe...

1 year ago - GlobeNewsWire

TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectus suppleme...

1 year ago - GlobeNewsWire

Profound Medical (PROF) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

TULSA-PRO, the most flexible prostate treatment on the market.

1 year ago - Seeking Alpha

TORONTO, May 20, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of...

1 year ago - GlobeNewsWire

Profound Medical Corp. (PROF) CEO Dr.

1 year ago - Seeking Alpha

PROFOUND MEDICL (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Profound Medical: The Prostate Market Disruptor

1 year ago - Seeking Alpha

Profound Medical, The Apple Of The Prostate Arena

1 year ago - Seeking Alpha

TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free...

1 year ago - GlobeNewsWire

Profound Medical: Non-Surgical Prostatectomy Is Profound

1 year ago - Seeking Alpha

TORONTO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free...

1 year ago - GlobeNewsWire

About PROF

Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with me... [Read more...]

Industry
Medical Devices
Stock Exchange
NASDAQ
Ticker Symbol
PROF
Full Company Profile

Financial Performance

In 2020, PROF's revenue was 7.30 million, an increase of 74.99% compared to the previous year's 4.17 million. Losses were -21.62 million, 42.0% more than in 2019.

Financial numbers in millions CAD.
Financial Statements